• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    AMERIPHARMA

    CMC Pharmaceuticals

    Societal CDMO

    Syngene International Ltd.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    AMERIPHARMA

    CMC Pharmaceuticals

    Societal CDMO

    Syngene International Ltd.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    OncoSec Collaborates with Providence Cancer Institute

    To conduct first-in-human trial of OncoSec's CORVax12, an investigational vaccine to prevent COVID-19

    Contract Pharma Staff04.07.20
    OncoSec Medical, a company developing late-stage intratumoral DNA‑based cancer immunotherapies, has teamed up with Providence Cancer Institute, a part of Providence St. Joseph Health, to pursue a first-in-human Phase 1 clinical trial of its novel DNA‑encodable, investigational vaccine, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19. 
     
    CORVax12 consists of OncoSec's existing product candidate, TAVO (interleukin-12 or "IL-12" plasmid), in combination with an immunogenic component of the SARS-CoV-2 virus recently developed by researchers at NIH's National Institute of Allergy and Infectious Diseases (NIAID) and licensed to OncoSec on a non-exclusive basis.
     
    Specifically, OncoSec's CORVax12 vaccine approach combines the co-administration of TAVO (plasmid IL-12) with a DNA-encodable version of the SARS-CoV-2 spike or "S" glycoprotein to enhance immunogenicity of the component developed by scientists at the NIAID Vaccine Research Center. CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.  We believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
     
    "Previous vaccine efforts against coronaviruses, including the SARS coronavirus, have focused on the S glycoprotein, which facilitates interaction with the host cell through binding to the ACE2 receptor," said Rom Leidner, co-medical director, head and neck cancer program at Providence Cancer Institute, and assistant member, Earle A. Chiles Research Institute and the principle investigator on the planned study. "Given the structural similarities between ACE2-receptor binding domain of the SARS-CoV-2 and SARS-CoV viruses, we would like to explore whether a similar strategy with OncoSec's CORVax12 may hold potential as an effective vaccine.  Importantly, we believe the delivery of CORVax12 using OncoSec's electroporation system may allow for highly effective DNA transfer to drive this investigational vaccine."
     
    Dr. Leidner continued, "Providence is among the U.S.'s largest, not-for-profit network of hospitals and includes 51 hospitals in Alaska, Washington, Oregon, Montana and California. We are positioned to rapidly initiate studies following FDA clearance of our IND and are hopeful that CORVax12, driven by OncoSec's IL-12 and NIH's spike DNA sequence, could have a meaningful impact on COVID-19 prevention and guide the development of a new generation of vaccines."
     
    Providence investigators have filed an Investigator-Initiated Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) and have designed a clinical trial protocol that will evaluate the vaccination of healthy adult volunteers utilizing OncoSec's next-generation, investigational APOLLO generator technology for the first time clinically if FDA clears the APOLLO to enter the clinic. The trial will also include extensive immune monitoring.
     
    "Teams of scientists at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, have moved quickly, using philanthropic support and experience from cancer vaccine manufacture to construct and manufacture the viral component of the CORVax12 vaccine that is licensed to OncoSec," said Bernard Fox, Harder Family Chair and Member of the Earle A. Chiles Research Institute.
     
    OncoSec will supply CORVax12 and its investigational APOLLO electroporation device to Providence as part of this effort and does not anticipate any additional capital commitment at this time. Additionally, OncoSec will contribute manufacturing, preclinical, and prior clinical information and data for TAVO, along with manufacturing data for its APOLLO technology, to support FDA's allowance of the Providence IND. Providence will hold the IND, if cleared by FDA, and perform the preclinical and clinical development work.
     
    "During a pandemic such as COVID-19, any opportunity to find a medical solution should be fully investigated," said Christopher Twitty, chief scientific officer, OncoSec. "We are excited to extend our deep expertise in IL-12 based immunotherapies along with an innovative vaccine candidate in support of the clinicians at Providence and their exploration of our CORVax12 vaccine to address this crisis. We hope to make a meaningful impact on COVID-19 as well as gaining a deeper understanding of its associated immunobiology."
     
    The anticipated work and clinical trials outlined above are subject to FDA allowance of the Investigator-Initiated IND filed by Providence.
     
    Fox 12 Oregon recently highlighted the efforts of Drs. Fox and Leidner from Providence regarding their work with CORVax12. Watch the video here.
    Related Searches
    • Clinical Trials
    • immunotherapies
    • late-stage
    • Development
      Loading, Please Wait..
      Breaking News
      • Univercells Expands into the U.S. With New Offices in Andover, MA
      • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
      • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
      • Sanner Group Opens Second Manufacturing Facility in China
      • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
      View Breaking News >
      CURRENT ISSUE

      September 2023

      • Pharma Supply Chains: From Fragile to Agile
      • Overcoming Stressors in Knowledge Transfer
      • Innovations in Pharma Packaging
      • HPAPI Manufacturing Trends
      • Sustainable Packaging in Pharma: No Longer a Pipe Dream
      • Revolutionizing Pharma’s Supply Chain
      • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
      • Solving Pharma’s Underlying Rebate Leakage Problem
      • Advanced Manufacturing and a Roadmap to the Facility of the Future
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
      Natrol Launches First Non-Melatonin Sleep Supplement
      Metagenics Releases Consumer Survey on Menopausal Support Supplement
      Coatings World

      Latest Breaking News From Coatings World

      Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
      California Sports Surfaces Celebrates 70 Years
      ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—Sept. 30
      Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
      SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Univercells Expands into the U.S. With New Offices in Andover, MA
      Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
      Ionis, Roche Partner on RNA-targeted Programs for AD and HD
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
      YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
      74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
      Happi

      Latest Breaking News From Happi

      Is Dr. Barbara Sturm Skincare Considering a Sale?
      YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
      Christian Siriano Appointed Olay’s First Chief Drop Officer
      Ink World

      Latest Breaking News From Ink World

      MicroDynamics, All Printing Resources Partner to Represent Veritas
      Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
      Siegwerk’s Climate Targets Validated by SBTi
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      SABIC and partners launch bio-based IML solution for food packaging
      tesa completes expansion of Michigan manufacturing facility
      Comexi and Asahi to host 'Effortless Platemaking' event
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Greentech Introduces Air Filter with Advanced Odor Elimination
      Ontex Divests Pakistan Operations to ASAIA Holding
      Goodnites Bedwetting Underwear Recognized by Good Housekeeping
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—Sept. 30
      Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
      ChitogenX Granted New U.S., Canadian ORTHO-R Patent
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
      Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
      Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login